Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Portfolio Pulse from
Moderna has received marketing authorization from the UK's MHRA for its RSV vaccine, mRESVIA, marking its second approved product in the UK. This vaccine is aimed at preventing lower respiratory tract disease caused by RSV in adults aged 60 and older.
February 28, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's RSV vaccine, mRESVIA, has received marketing authorization from the UK's MHRA, marking a significant milestone for the company in expanding its product offerings in the UK.
The approval of mRESVIA by the MHRA is a significant regulatory milestone for Moderna, potentially boosting its market presence and revenue in the UK. This approval could positively impact Moderna's stock price in the short term as it expands its product portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100